Osporil

Active Ingredient:: Zoledronic Acid
Origin:: EU

Osporil (Zoledronic Acid)

Q: What conditions is Osporil used to treat?

Osporil contains zoledronic acid, a bisphosphonate indicated for osteoporosis in post‑menopausal women and men at high risk, for preventing skeletal‑related events in patients with bone metastases, for treating hyper‑calcaemia of malignancy, and for managing Paget’s disease of bone.

Q: How does zoledronic acid work in the body?

Zoledronic acid binds to bone mineral at sites of active resorption and is taken up by osteoclasts, where it blocks the enzyme farnesyl‑pyrophosphate synthase in the mevalonate pathway. This inhibition prevents osteoclast maturation and activity, reducing bone breakdown and stabilising the skeleton.

Q: What is the usual dose of Osporil?

The dose of Osporil is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Healthcare professionals set the appropriate infusion volume and schedule.

Q: Is Osporil safe to use during pregnancy or breastfeeding?

Zoledronic acid is contraindicated in pregnancy and lactation because it may affect fetal bone development and is excreted in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should avoid this medication.

Q: How do I order Osporil from GNH India?

To order Osporil, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Osporil compare with other bisphosphonates?

Osporil (zoledronic acid) is a more potent, intravenously administered bisphosphonate compared with oral agents such as alendronate or risedronate. It requires less frequent dosing—typically once yearly for osteoporosis—while providing rapid calcium reduction in hyper‑calcaemia, but it also carries higher risks of acute‑phase reactions and renal effects.

Q: What are the storage requirements for Osporil?

Store Osporil at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light to maintain stability until the point of use.

Q: How is Osporil administered to patients?

Osporil is supplied as a sterile intravenous solution that is infused over a short period, usually 15 minutes, under medical supervision. The infusion rate and volume are set by the treating clinician according to the prescribed dose.

Q: What are the most serious risks associated with Osporil?

The most serious adverse events linked to zoledronic acid include osteonecrosis of the jaw, atypical femoral fractures, severe hypocalcaemia and acute kidney injury. Patients should be monitored closely for these complications, especially if they have pre‑existing risk factors.

Q: Who should not receive Osporil?

Osporil is contraindicated in patients with severe renal impairment (eGFR < 30 ml/min/1.73 m²), untreated hypocalcaemia, active dental infections, or in women who are pregnant or breastfeeding. Caution is also advised for individuals taking nephrotoxic drugs or high‑dose vitamin D.

Zoledronic Acid, the active ingredient in Osporil, is a bisphosphonate presented as a 4 mg/5 ml solution for intravenous use. It is used to treat bone loss conditions such as osteoporosis in post‑menopausal women and to reduce skeletal‑related events in patients with bone metastases. GNH India supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH India supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Osporil is a bisphosphonate that acts on bone‑remodelling disorders and related complications.

Osteoporosis: reduces the risk of vertebral and hip fractures in post‑menopausal women and men at high risk.
Bone metastases from solid tumours: lowers the incidence of skeletal‑related events such as pathological fractures and spinal cord compression.
Hypercalcaemia of malignancy: rapidly lowers elevated serum calcium levels in cancer patients.
Paget’s disease of bone: normalises bone turnover and alleviates bone pain.
Chronic kidney disease‑related mineral bone disorder: helps control secondary hyperparathyroidism and bone turnover.
Adjuvant therapy after breast cancer surgery: decreases the risk of bone loss associated with aromatase‑inhibitor treatment.

How It Works

Zoledronic acid binds with high affinity to hydroxy‑apatite crystals at sites of active bone resorption. Once internalised by osteoclasts, it inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, preventing prenylation of small GTP‑binding proteins essential for osteoclast function, leading to reduced bone resorption and increased skeletal stability.

Side Effects

Zoledronic acid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

Acute‑phase flu‑like symptoms: fever, myalgia, arthralgia, and headache shortly after infusion.
Gastro‑intestinal discomfort: nausea, abdominal pain, dyspepsia.
Musculoskeletal pain: transient bone or joint pain.
Transient hypocalcaemia: mild drops in serum calcium levels.
Injection‑site reactions: erythema or mild swelling at the infusion site.

Serious or Rare Side Effects

Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the maxillofacial region.
Atypical femoral fractures: low‑energy subtrochanteric or femoral shaft fractures.
Severe hypocalcaemia: clinically significant calcium depletion requiring medical intervention.
Renal impairment: acute kidney injury or worsening of pre‑existing renal dysfunction.
Anaphylaxis: rare systemic hypersensitivity reactions.

Precautions & Warnings

Before initiating therapy with zoledronic acid, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

Renal function: evaluate serum creatinine and calculate eGFR; adjust or avoid use if eGFR < 30 ml/min/1.73 m².
Calcium and vitamin D status: correct deficiencies prior to infusion to reduce hypocalcaemia risk.
Dental health: obtain dental evaluation and treat active infections before treatment to lower ONJ risk.
Concomitant medications: review use of nephrotoxic drugs, NSAIDs, and high‑dose corticosteroids.
Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding.
Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Zoledronic acid may interact with several medicines, altering its safety profile or efficacy.

Major Interactions (Avoid)

Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase risk of renal injury.
High‑dose vitamin D analogues: potentiate hypocalcaemia.
Bisphosphonate combination therapy: additive effects on bone turnover and renal function.

Moderate Interactions (Monitor Closely)

Loop diuretics: may exacerbate calcium loss.
Corticosteroids: increase risk of osteonecrosis of the jaw.
Antacids containing aluminium or magnesium: can affect absorption of calcium supplements used alongside therapy.

Frequently Asked Questions

Osporil contains zoledronic acid, a bisphosphonate indicated for osteoporosis in post‑menopausal women and men at high risk, for preventing skeletal‑related events in patients with bone metastases, for treating hyper‑calcaemia of malignancy, and for managing Paget’s disease of bone.

Zoledronic acid binds to bone mineral at sites of active resorption and is taken up by osteoclasts, where it blocks the enzyme farnesyl‑pyrophosphate synthase in the mevalonate pathway. This inhibition prevents osteoclast maturation and activity, reducing bone breakdown and stabilising the skeleton.

The dose of Osporil is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Healthcare professionals set the appropriate infusion volume and schedule.

Zoledronic acid is contraindicated in pregnancy and lactation because it may affect fetal bone development and is excreted in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should avoid this medication.

To order Osporil, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Osporil (zoledronic acid) is a more potent, intravenously administered bisphosphonate compared with oral agents such as alendronate or risedronate. It requires less frequent dosing—typically once yearly for osteoporosis—while providing rapid calcium reduction in hyper‑calcaemia, but it also carries higher risks of acute‑phase reactions and renal effects.

Store Osporil at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light to maintain stability until the point of use.

Osporil is supplied as a sterile intravenous solution that is infused over a short period, usually 15 minutes, under medical supervision. The infusion rate and volume are set by the treating clinician according to the prescribed dose.

The most serious adverse events linked to zoledronic acid include osteonecrosis of the jaw, atypical femoral fractures, severe hypocalcaemia and acute kidney injury. Patients should be monitored closely for these complications, especially if they have pre‑existing risk factors.

Osporil is contraindicated in patients with severe renal impairment (eGFR < 30 ml/min/1.73 m²), untreated hypocalcaemia, active dental infections, or in women who are pregnant or breastfeeding. Caution is also advised for individuals taking nephrotoxic drugs or high‑dose vitamin D.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.